4 results on '"Miguel Arreola"'
Search Results
2. Juvenile depletion of microglia reduces orientation but not high spatial frequency selectivity in mouse V1
- Author
-
Dario X. Figueroa Velez, Miguel Arreola, Carey Y. L. Huh, Kim Green, and Sunil P. Gandhi
- Subjects
Medicine ,Science - Abstract
Abstract Microglia contain multiple mechanisms that shape the synaptic landscape during postnatal development. Whether the synaptic changes mediated by microglia reflect the developmental refinement of neuronal responses in sensory cortices, however, remains poorly understood. In postnatal life, the development of increased orientation and spatial frequency selectivity of neuronal responses in primary visual cortex (V1) supports the emergence of high visual acuity. Here, we used the colony-stimulating factor 1 receptor (CSF1R) inhibitor PLX5622 to rapidly and durably deplete microglia in mice during the juvenile period in which increased orientation and spatial frequency selectivity emerge. Excitatory and inhibitory tuning properties were measured simultaneously using multi-photon calcium imaging in layer II/III of mouse V1. We found that microglia depletion generally increased evoked activity which, in turn, reduced orientation selectivity. Surprisingly, microglia were not required for the emergence of high spatial frequency tuned responses. In addition, microglia depletion did not perturb cortical binocularity, suggesting normal depth processing. Together, our finding that orientation and high spatial frequency selectivity in V1 are differentially supported by microglia reveal that microglia are required normal sensory processing, albeit selectively.
- Published
- 2022
- Full Text
- View/download PDF
3. A Trem2*R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques
- Author
-
Kristine M. Tran, Shimako Kawauchi, Enikö A. Kramár, Narges Rezaie, Heidi Yahan Liang, Miguel Arreola, Celia Da Cunha, Jimmy Phan, Sherilyn Collins, Amber Walker, Jonathan Neumann, Giedre Milinkeviciute, Angela Gomez-Arboledas, Dominic I. Javonillo, Katelynn Tran, Magdalena Gantuz, Stefania Forner, Vivek Swarup, Andrea J. Tenner, Frank LaFerla, Marcelo A. Wood, Ali Mortazavi, Grant R. MacGregor, and Kim N. Green
- Abstract
Genome-Wide Association Studies revealed the TREM2 R47H variant as one of the strongest genetic risk factors for late-onset Alzheimer’s Disease (AD). Unfortunately, many current TREM2*R47H mouse models are associated with cryptic mRNA splicing of the mutant allele that produces a confounding reduction in protein product. We have developed the Trem2R47H NSS (Normal Splice Site) mouse model where the Trem2 allele is expressed at a similar level to the wild-type Trem2 allele, without evidence of cryptic splicing products, and appropriate inflammatory responses to cuprizone challenge. Utilizing the 5xFAD mouse model, we report age- and disease-dependent changes in response to pathology. At an early disease stage (4 mo), homozygous Trem2R47H NSS; hemizygous 5xFAD (Trem2R47H NSS ; 5xFAD) mice have reduced size and number of microglia plus impaired interaction with plaques, that is associated with increased dystrophic neurites and axonal damage detected through plasma neurofilament light chain (NfL) level and suppressed inflammation. However, homozygosity for Trem2R47H NSS suppressed LTP deficits and presynaptic puncta loss caused by the 5xFAD transgene array. At a more advanced disease stage (12 mo,) Trem2R47H NSS ; 5xFAD mice no longer display impaired plaque-microglia interaction or suppressed inflammatory gene expression, although NfL levels remain elevated, and a unique interferon-related gene expression signature is seen. Furthermore, Trem2R47H NSS ; 5xFAD mice also display robust LTP deficits and exacerbated presynaptic loss. Collectively, we provide a Trem2R47H variant mouse without cryptic splicing, and demonstrate it has disease stage dependent effects when combined with a plaque bearing model, with an initial loss of function that ultimately resolves, giving rise to a unique interferon signature and associated tissue damage.
- Published
- 2022
4. Galactomannan as a Potential Modulator of Intestinal Ischemia-Reperfusion Injury
- Author
-
Martín Rumbo, Luis A. Aguirre, Pablo Stringa, Victor Toledano, Mariana Alejandra Machuca, Miguel Arreola, Rodrigo Papa-Gobbi, Carlota Largo, Francisco Hernández Oliveros, and Eduardo López-Collazo
- Subjects
Male ,Medicina ,medicine.medical_treatment ,Ischemia ,Pharmacology ,Mannans ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Downregulation and upregulation ,Digestive system surgical procedures ,medicine.artery ,medicine ,Animals ,Humans ,Superior mesenteric artery ,Intestinal Mucosa ,Interleukin 6 ,Receptor ,biology ,Chemistry ,Galactose ,purl.org/becyt/ford/3.1 [https] ,medicine.disease ,Small intestine ,Intestine ,Reperfusion injury ,Mesenteric ischemia ,Disease Models, Animal ,medicine.anatomical_structure ,Cytokine ,Jejunum ,030220 oncology & carcinogenesis ,Reperfusion Injury ,biology.protein ,030211 gastroenterology & hepatology ,Surgery ,purl.org/becyt/ford/3 [https] - Abstract
Background: Galactomannan (GAL), a polysaccharide present on the cell wall of several fungi, has shown an ability to modulate inflammatory responses through the dectin-1 receptor in human macrophages. However, studies evaluating the modulatory properties of this polysaccharide in in vivo inflammatory scenarios are scarce. We hypothesized that GAL pretreatment would modulate local and remote damage related to intestinal reperfusion after an ischemic insult. Materials and methods: Adult male Balb/c mice were subjected to intestinal ischemia–reperfusion injury by reversible occlusion of the superior mesenteric artery, consisting of 45 min of ischemia followed by 3 or 24 h of reperfusion. Intragastric GAL (70 mg/kg) was administered 12 h before ischemia, and saline solution was used in the control animals. Jejunum, lung, and blood samples were taken for the analysis of histology, gene expression, plasma cytokine levels, and nitrosative stress. Results: Intestinal and lung histologic alterations were attenuated by GAL pretreatment, showing significant differences compared with nontreated animals. Interleukin 1β, monocyte chemoattractant protein 1, and IL-6 messenger RNA expression were considerably downregulated in the small intestine of the GAL group. In addition, GAL treatment significantly prevented plasma interleukin 6 and monocyte chemoattractant protein 1 upregulation and diminished nitrate and nitrite levels after 3 h of intestinal reperfusion. Conclusions: GAL pretreatment constitutes a novel and promising therapy to reduce local and remote damage triggered by intestinal ischemia–reperfusion injury. Further in vivo and in vitro studies to understand GAL's modulatory effects are warranted., Facultad de Ciencias Veterinarias, Instituto de Estudios Inmunológicos y Fisiopatológicos
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.